Sonnet BioTherapeutics Holdings logo

Sonnet BioTherapeutics HoldingsNASDAQ: SONN

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

31 October 2006

Next earnings report:

13 December 2024

Last dividends:

N/A

Next dividends:

N/A
$1.85 M
-95%vs. 3y high
5%vs. sector
-vs. 3y high
-vs. sector
-97%vs. 3y high
32%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | 86 min ago
$2.85-$0.16(-5.32%)

Dividend

No data over the past 3 years

Analysts recommendations

Institutional Ownership

SONN Latest News

Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates
globenewswire.com06 November 2024 Sentiment: POSITIVE

Both novel bifunctional (SON-1411) and monofunctional (SON-1400) fusion proteins exhibit wild-type binding to the IL-18 receptor (IL-18Rc), coupled with undetectable binding to the inhibitory IL-18 binding protein (IL-18BP)

Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive Programs
globenewswire.com04 October 2024 Sentiment: POSITIVE

PRINCETON, NJ, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced it has received preliminary approval for a tax credit from the New Jersey Technology Business Tax Certificate Transfer Program administered by the New Jersey Economic Development Authority (NJEDA). Sonnet received approval of its application to sell up to $8,143,144 of its New Jersey State net operating losses (NOLs) and $62,810 of its New Jersey State research and development (R&D) tax credits for proceeds of up to $0.795 million through the New Jersey Technology Business Tax Certificate Transfer Program, subject to execution of such sale. Sonnet also expects to receive a $0.7 million net cash refund from the R&D Tax Incentive Program in Australia.

Sonnet BioTherapeutics Announces Launch of CEO Corner Platform
globenewswire.com30 September 2024 Sentiment: POSITIVE

CEO Corner segments to include additional discussion related to press releases, events, corporate updates and pipeline progress

Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split
globenewswire.com25 September 2024 Sentiment: NEUTRAL

PRINCETON, N.J., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (“Sonnet” or the “Company”) (NASDAQ: SONN), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that it will effect a 1-for-8 reverse stock split of its outstanding common stock. This will be effective for trading purposes as of the commencement of trading on Monday, September 30, 2024.

Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell Series
globenewswire.com04 September 2024 Sentiment: POSITIVE

PRINCETON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced that it will participate in the Virtual Investor Closing Bell Series on Monday, September 9, 2024, at 4:00 PM ET.

Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
globenewswire.com14 August 2024 Sentiment: POSITIVE

Ongoing progress with both clinical trials of lead program, SON-1010, for solid tumors and Platinum-Resistant Ovarian Cancer (PROC)

Sonnet BioTherapeutics (NASDAQ:SONN) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team
accesswire.com24 July 2024 Sentiment: POSITIVE

Watch the "What This Means" segment here FRENCHTOWN, NJ / ACCESSWIRE / July 24, 2024 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today released a Virtual Investor "What This Means" segment featuring Sonnet BioTherapeutics, Inc. (Nasdaq:SONN), a clinical-stage company developing targeted immunotherapeutic drugs. As part of the "What This Means" segment, Pankaj Mohan, PhD, Founder and Chief Executive Officer, Richard Kenney, M.D.

Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting
globenewswire.com28 May 2024 Sentiment: POSITIVE

PRINCETON, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that the SB221 study of SON-1010 (recombinant human Interleukin-12 linked to Sonnet's fully-human albumin binding domain or IL12-FHAB) dosed in combination with atezolizumab (Tecentriq®) will be presented as a ‘Trial in Progress' poster at ASCO 2024. Study SB221 (NCT05756907) is a Phase 1b/2a multicenter, dose-escalation, and proof-of-concept clinical study to assess the safety, tolerability, PK, PD, and efficacy of SON-1010 administered SC, either alone or in combination with a fixed dose of atezolizumab given IV. The work will be presented in a poster session at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting 2024, to be held May 31 to June 4 in Chicago, Illinois.

Why Is Sonnet BioTherapeutics (SONN) Stock Down 33% Today?
InvestorPlace25 October 2023 Sentiment: NEGATIVE

Sonnet BioTherapeutics (NASDAQ: SONN ) stock is falling on Wednesday after the biotechnology company revealed details of a public share offering. That public stock offering has Sonnet BioTherapeutics selling 2,843,750 shares of SONN stock at a price of $1.60 each.

Why Is Sonnet BioTherapeutics (SONN) Stock Down 5% Today?
InvestorPlace31 July 2023 Sentiment: NEGATIVE

Sonnet BioTherapeutics (NASDAQ: SONN ) stock is taking a beating on Monday after the company announced a public stock offering. Investors will note that this public stock offering comes from selling stockholders and not directly from Sonnet BioTherapeutics.

What type of business is Sonnet BioTherapeutics Holdings?

Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey.

What sector is Sonnet BioTherapeutics Holdings in?

Sonnet BioTherapeutics Holdings is in the Healthcare sector

What industry is Sonnet BioTherapeutics Holdings in?

Sonnet BioTherapeutics Holdings is in the Biotechnology industry

What country is Sonnet BioTherapeutics Holdings from?

Sonnet BioTherapeutics Holdings is headquartered in United States

When did Sonnet BioTherapeutics Holdings go public?

Sonnet BioTherapeutics Holdings initial public offering (IPO) was on 31 October 2006

What is Sonnet BioTherapeutics Holdings website?

https://www.sonnetbio.com

Is Sonnet BioTherapeutics Holdings in the S&P 500?

No, Sonnet BioTherapeutics Holdings is not included in the S&P 500 index

Is Sonnet BioTherapeutics Holdings in the NASDAQ 100?

No, Sonnet BioTherapeutics Holdings is not included in the NASDAQ 100 index

Is Sonnet BioTherapeutics Holdings in the Dow Jones?

No, Sonnet BioTherapeutics Holdings is not included in the Dow Jones index

When was Sonnet BioTherapeutics Holdings the previous earnings report?

No data

When does Sonnet BioTherapeutics Holdings earnings report?

The next expected earnings date for Sonnet BioTherapeutics Holdings is 13 December 2024